Quarterly report · Q1
7446.TEDINET S100ST6L
Period2023-10-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.3bn | 2023-10-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥35.1bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.4bn | 2022-10-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥58m | 2023-10-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥254m | 2022-10-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥78m | 2023-10-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥808m | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥271m | 2022-10-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥90m | 2023-10-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥271m | 2022-10-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥53m | 2023-10-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥556m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥182m | 2022-10-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥53m | 2023-10-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥187m | 2022-10-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥19.7bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥18.9bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥19.2bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥12.4bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥11.7bn | at 2023-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥7.3bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.3bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-09-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥59.34 | 2023-10-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥617.29 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.31 | 2022-10-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 36.5% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.7% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E02810-000Academia Life Science Sales Groupreportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥518m |
| jpcrp040300-q1r_E02810-000Academia Life Science Sales Groupreportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥518m |
| jpcrp040300-q1r_E02810-000Industry Sales Groupreportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥4.2bn |
| jpcrp040300-q1r_E02810-000Industry Sales Groupreportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥4.2bn |
| jpcrp040300-q1r_E02810-000Medical Sales Groupreportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥3.6bn |
| jpcrp040300-q1r_E02810-000Medical Sales Groupreportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥3.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-10-01 → 2023-12-31 | ¥8.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-10-01 → 2023-12-31 | ¥8.3bn |
| jpcrp040300-q1r_E02810-000Academia Life Science Sales Groupreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥552m |
| jpcrp040300-q1r_E02810-000Academia Life Science Sales Groupreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥552m |
| jpcrp040300-q1r_E02810-000Industry Sales Groupreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥4.6bn |
| jpcrp040300-q1r_E02810-000Industry Sales Groupreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥4.6bn |
| jpcrp040300-q1r_E02810-000Medical Sales Groupreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥4.3bn |
| jpcrp040300-q1r_E02810-000Medical Sales Groupreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-10-01 → 2022-12-31 | ¥9.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-10-01 → 2022-12-31 | ¥9.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 365
| Item | Context | Value | Unit |
|---|---|---|---|
| Income before income taxes | Prior1YTDDuration | 271409000 | JPY |
| Income before income taxes | CurrentYTDDuration | 89729000 | JPY |
| Income taxes current | Prior1YTDDuration | 67391000 | JPY |
| Income taxes current | CurrentYTDDuration | 15517000 | JPY |
| Income taxes deferred | Prior1YTDDuration | 17470000 | JPY |
| Income taxes deferred | CurrentYTDDuration | 21584000 | JPY |
| Income taxes | Prior1YTDDuration | 84861000 | JPY |
| Income taxes | CurrentYTDDuration | 37102000 | JPY |
| Profit loss | Prior1YTDDuration | 186547000 | JPY |
| Profit loss | CurrentYTDDuration | 52626000 | JPY |
| Profit loss attributable to non controlling interests | Prior1YTDDuration | 4263000 | JPY |
| Profit loss attributable to non controlling interests | CurrentYTDDuration | -840000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 182284000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 53467000 | JPY |
| Profit loss | Prior1YTDDuration | 186547000 | JPY |
| Profit loss | CurrentYTDDuration | 52626000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | -31694000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | 50151000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | 425000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | 154000 | JPY |
| Other comprehensive income | Prior1YTDDuration | -31268000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 50306000 | JPY |
| Comprehensive income | Prior1YTDDuration | 155279000 | JPY |
| Comprehensive income | CurrentYTDDuration | 102932000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 151016000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 103842000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 4262000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | -909000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E02810-000IndustrySalesGroupReportableSegmentMember | 4604421000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E02810-000MedicalSalesGroupReportableSegmentMember | 4252528000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 552349000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 9409299000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 9409299000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E02810-000IndustrySalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E02810-000MedicalSalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E02810-000IndustrySalesGroupReportableSegmentMember | 4604421000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E02810-000MedicalSalesGroupReportableSegmentMember | 4252528000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 552349000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 9409299000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 9409299000 | JPY |
| Gross profit | Prior1YTDDuration_jpcrp040300-q1r_E02810-000IndustrySalesGroupReportableSegmentMember | 391251000 | JPY |
| Gross profit | Prior1YTDDuration_jpcrp040300-q1r_E02810-000MedicalSalesGroupReportableSegmentMember | 403526000 | JPY |
| Gross profit | Prior1YTDDuration_jpcrp040300-q1r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 74683000 | JPY |
| Gross profit | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 869460000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |